Sobi™ completes acquisition of Synagis® US rights from AstraZeneca and exercises authorisation to issue shares
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US, as announced on 13 November 2018. Synagis is a medicine for the prevention of serious lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in high-risk infants and is the only approved preventative medicine for the condition. MEDI8897 is a follow-on